Gossamer Bio/$GOSS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Gossamer Bio
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension).
Ticker
$GOSS
Sector
Primary listing
Employees
162
Headquarters
Website
Gossamer Bio Metrics
BasicAdvanced
$85m
-
-$0.78
2.15
-
Price and volume
Market cap
$85m
Beta
2.15
52-week high
$3.87
52-week low
$0.14
Average daily volume
17m
Financial strength
Current ratio
2.204
Quick ratio
1.921
Long term debt to equity
-125.076
Total debt to equity
-125.668
Interest coverage (TTM)
-15.58%
Profitability
EBITDA (TTM)
-171.286
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-324.82%
Operating margin (TTM)
-308.46%
Effective tax rate (TTM)
0.05%
Revenue per employee (TTM)
$340,000
Management effectiveness
Return on assets (TTM)
-52.29%
Return on equity (TTM)
215.10%
Valuation
Price to revenue (TTM)
0.718
Price to book
-0.25
Price to tangible book (TTM)
-0.25
Price to free cash flow (TTM)
-0.234
Free cash flow yield (TTM)
-426.91%
Free cash flow per share (TTM)
-0.739
Growth
Revenue change (TTM)
-55.42%
Earnings per share change (TTM)
246.19%
3-year earnings per share growth (CAGR)
-31.84%
What the Analysts think about Gossamer Bio
Analyst ratings (Buy, Hold, Sell) for Gossamer Bio stock.
Gossamer Bio Financial Performance
Revenues and expenses
Gossamer Bio Earnings Performance
Company profitability
Gossamer Bio News
AllArticlesVideos
Gossamer Bio, Inc. Announces Determination of Conversion Rate for 7.50% Convertible Senior Secured First Lien Notes due 2030 and Exercise Price for Purchase Warrants
Business Wire·3 days ago
Gossamer Bio, Inc. Announces Final Tender Results for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes
Business Wire·2 weeks ago
CLASS ACTION DEADLINE TONIGHT: Gossamer Bio (GOSS) Investors Who Suffered Losses Encouraged to Contact Faruqi & Faruqi Before June 1, 2026 Securities Class Action Deadline
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs